Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Sponsor: NS Pharma, Inc.
This PHASE1/PHASE2 trial investigates Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis and is currently completed. NS Pharma, Inc. leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NS Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .